Company news
Proteomics International Laboratories Ltd. (ASX:PIQ) news
Proteomics International Laboratories Ltd. news releases on 6ix. Latest, Sep 14, 2026: PromarkerD and PromarkerEso Commercial Rollout Update
Press releases & updates
PromarkerD and PromarkerEso Commercial Rollout Update
September 13, 2026
Appendix 4E and Annual Report
August 31, 2026
Australian patent for PromarkerEndo
August 12, 2026
Proteomics signs national distribution deal with Healius
July 21, 2026
US patent secured for PromarkerEndo
July 7, 2026
Proteomics Strategic Plan
April 27, 2026
Restructure, Executive Appointment and Board Update
April 16, 2026
Appendix 4D and Interim Financial Report
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Canadian patent secured for PromarkerEso test for EAC
January 15, 2026
Appointment of CEO and Managing Director
January 13, 2026
Proteomics US lab CAP accredited - extends precision Dx lab
December 23, 2025
US patent secured for PromarkerEso diagnostic test for EAC
December 16, 2025
PromarkerD predicts risk of DKD in Aboriginal Australians
December 14, 2025
Response to ASX Price Query
December 2, 2025
US Medicare sets reimbursement price for PromarkerD DKD test
November 25, 2025
OxiDx test correlates with superior racehorse performance
November 23, 2025
Proteomics International receives $2.2m in R&D tax incentive
November 11, 2025
PromarkerEndo test for endometriosis receives $0.5m grant
November 6, 2025
Collaboration expanded to advance Endometriosis blood test
October 14, 2025
Proteomics granted certification for Diagnostics Laboratory
September 17, 2025
Board and Management Transition
September 8, 2025
PromarkerEso precisely detects early stage esophageal cancer
September 7, 2025
Preliminary Final Report
August 26, 2025
OxiDx test detects muscle damage in thoroughbred racehorses
July 13, 2025
AMA grants reimbursement code for Next-Gen PromarkerD test
July 2, 2025
Funding boost for precision diagnostics Proteomics Facility
June 30, 2025
First patent for endometriosis blood test - granted in Japan
June 29, 2025
PromarkerD launched into the US at major diabetes conference
June 19, 2025
Supplementary Prospectus
June 5, 2025
A landmark in non-invasive Esophageal Cancer diagnosis
June 4, 2025
$12 million capital raise completed with oversubscribed SPP
June 4, 2025
PromarkerEndo latest results presented at world congress
May 25, 2025
Chinese patent granted for OxiDx technology
May 14, 2025
Share Purchase Plan Offer Booklet
May 5, 2025
$4.5m placement to launch Promarker diagnostics
April 22, 2025
Trading Halt
April 16, 2025
Pause in Trading
April 16, 2025
Australian patent granted for OxiDx oxidative stress test
March 27, 2025
Response to ASX Aware Query
March 16, 2025
PromarkerD predictive test for DKD launched in Australia
March 12, 2025
PromarkerD outperforms conventional tests--results published
March 10, 2025
Proteomics opens CLIA certified reference laboratory in USA
February 27, 2025
Interim Financial Report and Appendix 4D
February 25, 2025
December 2024 Quarterly Activities Report and Appendix 4C
January 20, 2025
Novel OxiDx test detects muscle damage in elite athletes
December 30, 2024
Breakthrough results for endometriosis diagnostic blood test
December 29, 2024
Proteomics receives $2.16 million in R&D tax incentive
December 15, 2024
AGM Chairman's Address and Investor Presentation
November 8, 2024
September 2024 Quarterly Activities Report and Appendix 4C
October 21, 2024